Background Doxorubicin (Dox) depletes p300 from cardiac myocytes and induces apoptosis of these cells. p300 protein possesses ubiquitin ligase activity for the p53 tumor suppressor gene product, catalyzes p53 polyubiqutination, and facilitates p53 degradation in an ubiquitin-dependent manner. The present study investigated the ubiquitin-dependent regulation of p53 by Dox and p300 in cardiac myocytes. Methods and Results Primary cardiac myocytes from neonatal rats were exposed to a proteasome inhibitor, MG132, in culture. MG132 increased both p300 and p53 protein levels in these cells, suggesting that ubiquitindependent degradation is involved in the homeostasis of these proteins. Notably, treatment of cardiac myocytes with Dox decreased the protein levels of p300 but markedly increased those of p53. By immunoprecipitationWestern blotting, it was shown that treatment with Dox decreased poly-ubiquitinated p53 but increased that of p300 in cardiac myocytes. Finally, the overexpression of p300 in cardiomyocytes suppressed the Dox-mediated increase in the p53 level in addition to inhibiting Dox-induced apoptosis. Conclusion Dox reciprocally regulates p300 and p53 through ubiquitin-dependent pathways and that p300, by its ubiquitin ligase activity, is partially involved in the ubiquitin-dependent degradation of p53 in cardiac myocytes. (Circ J 2008; 72: 1506 -1511 
eart failure is a final stage of various cardiac diseases such as hypertensive heart disease, valvular heart disease and ischemic heart disease. Although the precise mechanisms that cause heart failure have not been fully elucidated, loss of cardiac myocytes is commonly observed in cardiac tissues from patients with end-stage heart failure. Cardiomyocyte apoptosis is now recognized as one of the important modes of cell death that is responsible for myocyte loss. [1] [2] [3] Long-term inhibition of caspase, a final executer of apoptosis, has been demonstrated to decrease cardiomyocyte apoptosis and improve left ventricular function after myocardial infarction, 4 suggesting that apoptosis significantly contributes to the development of heart failure. Therefore, elucidation of the precise mechanisms that regulate apoptosis is critical to establish a novel therapeutic strategy for heart failure. p300 was originally identified as a protein that binds to the adenoviral E1A gene region and is now recognized as a transcriptional co-activator that possesses histone acetyltransferase activity. 5 When adenovirus E1A oncoprotein is expressed in differentiated cardiac muscle cells, it represses muscle-specific gene expression and induces apoptosis. Studies of E1A mutants suggest that interference with the transcriptional co-activator functions of p300 is sufficient to induce apoptosis in cardiac myocytes. 6 Doxorubicin (Dox) is an anti-tumor agent that dramatically reduces the amount of p300 protein in cardiac myocytes. 7, 8 Similar to the effect of E1A expression, Dox represses muscle-specific gene expression and induces apoptosis in cardiac myocytes, 9 and causes cardiomyopathy and heart failure in vivo. Our previous report demonstrated that overexpression of p300 ameliorates the extent of Dox-induced acute heart failure in adult mice in vivo. 10 These findings suggest a role for p300 in myocardial cell survival.
The p53 tumor suppressor possesses pro-apoptotic activities, 11 and p53 alone is sufficient to induce myocardial cell apoptosis. 12 Degradation of p53 by the proteasome is essential for its physiologic regulation and requires ubiquitin ligases. Mdm2 acts as a specific E3 ligase for p53 by adding ubiquitin chains under normal conditions. p53 is ubiquitinated within the nucleus, shuttled into the cytoplasm either directly or indirectly by Mdm2, and then recognized by the 26S proteasome for degradation. 13 It has recently been reported that p300 cooperates with Mdm2 and acts as a specific ubiquitin E4 ligase for p53. Therefore, p300 catalyzes p53 polyubiqutination, facilitates p53 degradation in a ubiquitin-dependent manner, and is able to inhibit p53-mediated apoptosis. 14 However, it is unknown whether the activity of p300 as a ubiquitin ligase for p53 plays a role in Dox-induced apoptosis. Therefore, the present study investigated the ubiquitin-dependent regulation of p53 by Dox and p300 in cardiac myocytes.
Methods

Plasmid Constructs
Expression vectors pCMV--gal (Santa Cruz Biotechnology, Santa Cruz, CA, USA), pCI-p300 (a gift from Dr Yoshihiro Nakatani, Dana -Farber Cancer Institute, Harvard Medical School, USA), pcDNA3-p53 (a gift from Dr Kunitada Shimotohno, Kyoto University, Japan) and pMT123 (a gift from Dr Jonathan Leis, Northwest University, USA) contain the cytomegalovirus promoter/enhancer fused to -galactosidase cDNA, a full-length FLAG-tagged human p300 cDNA, a full-length human p53 cDNA, and HA-tagged ubiquitin cDNA, respectively.
Cell Culture and Transfection
Primary neonatal rat ventricular cardiac myocytes were prepared, and DNA was transfected using LipofectAMINE PLUS (Invitrogen) as described previously. 15, 16 
Immunoprecipitation and Western Blotting
Western blotting was performed as previously described. 17, 18 For the detection of p300, p53, phospho-p53 (ser-15) -catenin and -actin, we used an anti-p300 polyclonal antibody (Santa Cruz Biotechnology), anti-p53 polyclonal antibody (Santa Cruz Biotechnology), anti-phosphop53 (ser-15) polyclonal antibody (Cell Signaling, Danvers, MA, USA), and anti--actin monoclonal antibody (SIGMA), respectively. In Western blotting for caspase-3, we used anticaspase-3 polyclonal antibody (Santa Cruz Biotechnology) that recognizes full-length caspase-3, and anti-cleaved caspase-3 polyclonal antibody (Cell Signaling) that specifically reacts with the active p17 subunit of caspase-3.
Ubiquitination Assay Using Immunoprecipitation
Cardiac myocytes were co-transfected with pMT123 and with either pCI-p300 or pcDNA3-p53. Twenty-four hours later, these cells were treated with either saline or 3 mol/L Dox in the presence of MG132 and further incubated for 24 h. Whole cell lysates from these cells were immunoprecipitated with anti-FLAG antibody-conjugated agarose (SIGMA) for p300 and with anti-p53 polyclonal antibody for p53 in RIPA buffer for 4 h at 4°C. The immunoprecipitates were then incubated with protein A beads (Amersham Biosciences, Tokyo, Japan) for 2 h at 4°C, washed 4 times in the same buffer and subjected to Western blotting by using an anti-HA mouse monoclonal antibody (Santa Cruz Biotechnology).
Gene Expression Analysis by Real-Time RT-PCR
Total RNA was isolated from cardiac myocytes using TRIzol ® Reagent (Invitrogen). RNA samples were treated with DNaseI (Invitrogen) to eliminate genomic DNA contamination, and cDNA was synthesized using SuperScript TMII reverse transcriptase (Invitrogen). For real-time PCR, the reaction was performed with a SYBR ® Green PCR Master Mix (Applied Biosystems) and the products were analyzed with a thermal cycler (ABI Prism ® 7900HT, Sequence Detection System). Levels of GAPDH transcript were used to normalize cDNA levels. Gene-specific primers for p53 and p300 were generated as previously described. 10 
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In Situ Labeling of Apoptotic Cells and Quantitative Analysis
Terminal deoxynucleotidyl transfer-mediated end-labeling of fragmented nuclei (TUNEL assay) was performed in accordance with the manufacturer's protocol (Takara Biomedicals, Otsu, Japan) as previously described. 10 Individual nuclei were observed at a magnification of 400×, and an average of 500 nuclei from at least 20 independent fields were analyzed in each slide. The apoptotic index (percentage of apoptotic nuclei) was calculated as: (apoptotic nuclei/total nuclei) ×100%. Samples were scored blindly and samples from at least 3 independent experiments were scored per group.
Statistical Analysis
Data are presented as the mean ± SE. Statistical comparisons were performed using unpaired 2-tailed Student's t-tests or ANOVA with Scheffe's test where appropriate, with a probability value less than 0.05 taken to indicate significance.
Results
p300 Protects Cardiac Myocytes From Dox-Induced Apoptosis
First, to examine whether expression of p300 inhibits Dox-induced apoptosis in cultured neonatal rat cardiac myocytes, these cells were transfected with either pCI-p300 or pCMV--gal and then treated with either saline or Dox. Forty-eight hours later, we performed TUNEL-staining and Western blotting for caspase-3, a final death executor. Dox treatment increased the percentage of TUNEL-positive myocytes and the cleavage of caspase-3 in a dose-dependent manner. Forced expression of p300 significantly suppressed these increases (Figs 1A-C). These findings provide the evidence for p300-mediated inhibition of Dox-induced apoptosis in cardiac myocytes.
Reciprocal Regulation of p53 and p300 by Dox in Cardiac Myocytes
To determine whether Dox regulates the protein levels of p53 and p300 in cardiac myocytes and whether the ubiquitin-proteosome system is involved in the regulation, we treated primary cardiac myocytes from neonatal rats with a proteasome inhibitor, MG132, or its solvent, DMSO, in the presence or absence of Dox for 24 h. Then, protein extracts were subjected to Western blot analysis. As shown in Fig 2A, in the basal state (in the absence of Dox), treatment of cardiac myocytes with MG132 markedly increased p53 and p300 protein levels, suggesting that ubiquitin-dependent degradation is involved in the homeostasis of p53 and p300. Consistent with previous reports, treatment of cardiac Regulation of p300 and p53 mRNA levels in cardiac myocytes by doxorubicin and a proteasome inhibitor MG132. Neonatal cardiocytes were with MG132 in the presence or absence of 3 mol/L doxorubicin for 6 h. Total RNA was extracted and synthesized cDNA was subjected to real-time PCR. The amounts of cDNA for the p300 (A) and p53 (B) and GAPDH genes were measured. Levels of GAPDH transcripts were used to normalize cDNA levels. The amount of PCR products amplified from untreated neonatal cardiocytes was set 1.0 in each experiment. myocytes with Dox decreased the p300 protein level. The proteasome inhibitor, MG132, rescued the Dox-mediated decrease in the p300 level, suggesting that the ubiquitinproteasome system is involved in the Dox-mediated decrease of p300 in cardiac myocytes. In contrast to the effect on p300, treatment of cardiac myocytes with Dox markedly increased the levels of p53 protein, while MG132 did not affect the p53 level in the Dox-treated state. The level of a phosphorylated form (active form) of p53 was increased by MG132 in the basal state and by Dox in the absence of MG132, concomitant with the increase in p53. Neither Dox nor MG132 changed the level of Mdm2. Next, we subjected cultured cardiac myocytes to Dox for different durations and at different doses. Treatment of cardiac myocytes with Dox decreased protein levels of p300 and increased those of p53 in time- (Fig 2B) and dose-dependent (Fig 2C) manners. The Dox-induced decrease of p300 was well correlated with the increase of p53. Thus, Dox reciprocally regulates p53 and p300 proteins in cardiac myocytes.
To examine whether Dox affects mRNA levels of p300 and p53 in cardiac myocytes, we performed quantitative RT-PCR. Consistent with the data from Western blots, mRNA levels of p300 decreased in the presence of Dox (Fig 3A) . In contrast, mRNA levels of p53 decreased with Dox, which was inconsistent with its protein levels ( Fig 3B) . As p53 is expressed at low or undetectable levels with a short half-life because of its rapid degradation by proteasome, protein levels of p53 might be dependent on ubiquitination rather than transcription.
Ubiquitin-Dependent Degradation is Involved in Dox-Mediated Regulation of p53 and p300 in Cardiac Myocytes
To determine whether Dox affects the protein degradation of p53 and p300 via the ubiquitin-proteasome system, we examined the poly-ubiquitination of these proteins. Their poly-ubiquitinated forms are recognized by the 26S proteasome machinery and degraded quickly. Cardiac myocytes were cotransfected with pCI-p300/pMT123 (Fig 4A) or pcDNA3-p53/pMT123 (Fig 4B) , and treated with either saline or 3 mol/L Dox with MG132 for 24 h. Whole cell lysates from these cells were subjected to immunoprecipitation with anti-FLAG antibody (Fig 4A) for p300 or anti-p53 antibody for p53 ( Fig 4B) followed by Western blotting using the anti-HA antibody for ubiquination. As shown in Fig 4A , treatment of cardiac myocytes with Dox significantly increased the poly-ubiquitinated form of p300. These findings suggest that the mechanism of the Dox-induced decrease in the p300 level involves an increase in the ubiquitin-dependent protein degradation. In contrast, Dox treatment markedly decreased poly-ubiquitinated p53 in cardiac myocytes (Fig 4B) , suggesting that a decrease in the ubiquitin-dependent degradation mediates the Dox-induced increase of p53.
Forced Expression of p300 Partially Reduces the p53 Level in Cardiac Myocytes
Next, to determine whether the p300-mediated inhibition of Dox-induced myocardial cell apoptosis involves an ubiquitin-dependent mechanism, neonatal rat ventricular cardiac myocytes were transfected with either an expression vector encoding p300 (pCI-p300) or one encoding -galactosidase (pCMV--gal) as a control. Subsequently, the cells were treated with saline or Dox for 24 h. Protein extracts prepared from these cells were subjected to Western blotting using an anti-p300 or anti-p53 antibody. As shown in Fig 5, the protein level of p300 was markedly increased by transfection of pCI-p300 compared with transfection of pCMV- Fig 5 . Forced expression of p300 partially reduces the p53 level in cardiac myocytes. Neonatal cardiomyocytes were transfected with either pCMV--gal or pCI-p300. Twenty-four hours later, these cells were treated with culture medium containing 3 mol/L doxorubicin or saline as a control, and further incubated for 24 h. Protein extracts (20 g ) from these cells were subjected to Western blotting by using anti-p300, -p53, -phospho-p53 and --actin antibodies. Doxorubicin reciprocally regulates proteasome-mediated degradation of p300 and p53 in cardiac myocytes. Neonatal cardiocytes were cotransfected with either pCI-p300 (A) or pcDNA3-p53 (B) and pMT123. Twenty-four hours later, these cells were treated with 0.3 mol/L of MG-132 in the presence or the absence of 3 mol/L doxorubicin, and further incubated for 24 h. Cell lysates from these cells were immunoprecipitated with an anti-FLAG antibody for p300 (A) or anti-p53 antibody for p53 (B). The precipitates were subjected to Western blotting by using an anti-HA mouse monoclonal antibody and an antibody for either p300 or p53.
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The results of this study slightly differ from our previous in vivo data. For example, we showed that Dox significantly suppressed p300 and Mdm2 but did not affect p53 protein levels in wild-type adult mice hearts. 10 In p300 transgenic mice, Dox did not affect the p53 protein level even in the p300-and Mdm2-upregulated conditions. Dox sensitivities greatly differ between in vitro and in vivo conditions. In vitro, 48 h after Dox stimulation (0.3 mol/L), more than 30% of cardiac myocytes entered apoptosis. In contrast, 3 days after the injection of Dox, less than 0.08% of apoptotic cardiac myocytes were detected in the hearts of Dox-treated mice in vivo. Thus, the discrepancy in protein expression might be attributable to environmental differences between in vitro and in vivo conditions. Dysfunction of the ubiquitin-proteasome system has been implicated in the pathogenesis of numerous disorders, including neurodegenerative disease 22 and muscular dystrophy. 23 The marked accumulation of ubiquitinated proteins in cardiomyocytes of human failing hearts suggests that impairment of the ubiquitin-proteasome system is involved in the development of heart failure. 24, 25 Proteasome activities decrease and proapoptotic proteins such as p53 and Bax increase in pressure-overloaded hearts. 25 Meanwhile, it has been reported that Dox enhances the function of the ubiquitin-proteasome system. 26 Our finding that Dox enhances p300 degradation in cardiac myocytes is compatible with this report. By contrast, Dox reduces ubiquitin-dependent proteasomal degradation of p53 and induces the accumulation of p53, similar to the alterations in pressure-overloaded hearts. These findings suggest that the regulation of the ubiquitin-proteasome system in cardiac myocytes is complex and differs for each molecule. At least 3 ubiquitin ligases other than p300 exist, including Mdm2, Cop-1 and Pirh-1. 27, 28 Recently, it has been reported that ubiquitinrelated autophagic cell death of cardiomyocytes in failing hearts provides an adaptive response to hemodynamic stress. 29 Elucidation of the precise mechanisms that control the ubiquitin-proteasome system in cardiac myocytes will shed new light on the pathophysiology of heart failure.
-gal. The level of p300 was decreased by Dox treatment in both pCI-p300-and pCMV--gal-transfected cardiac myocytes. Compared with the control, forced expression of p300 partially, but not completely, downregulated both total-p53 and phospho-p53 protein levels in these cells.
Discussion
The tumor suppressor protein p53 is a transcription factor and a mediator of apoptosis in various cell types. Having a short half-life, p53 is normally maintained at low levels in unstressed mammalian cells. 20 The present study demonstrated that the proteasome inhibitor, MG132, markedly increased the p53 level in cardiac myocytes in the basal state, suggesting that continuous ubiquitination and subsequent degradation by the 26S proteasome is involved in the homeostasis of p53. We found that Dox stimulation markedly increased the p53 level. It has been reported that p53 alone is sufficient to induce apoptosis in cardiac myocytes, 12 suggesting that induction of p53 is involved in Doxinduced apoptosis.
The present study also demonstrated that Dox markedly reduced the poly-ubiquitinated form of p53 in cardiac myocytes. These findings suggest that a decrease in proteasomedependent degradation is a major mechanism of the Doxinduced increase in the p53 level. p300 not only possesses an intrinsic histone acetyltansferase activity but also ubiquitin ligase activitiy, thus promoting p53 ubiquitination and subsequent proteasomal degradation. 14 Overexpression of p300 in cardiac myocytes partially suppressed the Doxinduced increase in the p53 level. It is unclear at present whether this partial suppression provides a mechanism by which p300 inhibits Dox-induced apoptosis. However, Dox did not change the level of Mdm2, a major ubiquitin ligase for p53. In cardiac myocytes, as the cell cycle almost completely arrests, p53 protein is kept at very low levels in basal states. Toth et al reported that a small increase in p53 protein levels by hypoxia in cardiac myocytes markedly induced their apoptosis. 21 Therefore, even if the decrease in p53 protein levels is subtle, it might be protective against Dox-induced apoptosis. However, we cannot rule out the possibility that mechanisms other than p53 are involved in p300-mediated inhibition of cardiomyocyte apoptosis.
The precise molecular mechanism of the reciprocal regulation of p53 and p300 by Dox is unclear at present. Poizat et al reported that p38 mitogen-activated kinase activated by Dox phosphorylates p300, and that this phosphorylation induces ubiquitin proteasome-dependent degradation of p300. 7 This provides a mechanism of p300 depletion by Dox. In contrast, Grossman et al reported that p300 E4 ubiquitin ligase activity is required for p53 polyubiquitination. 14 The interaction of p53 with Mdm2 and p300 plays a critical role in the ubiquitination and degradation of p53. Therefore, one might speculate that the induction of p53 protein by Dox results from the loss of p300. According to this speculation, normal p53 turnover should be restored by the forced expression of p300 in cells treated with Dox. However, the present study demonstrated that the forced expression of p300 only slightly decreased the protein level of p53. This unexpected result might be attributable to Dox suppressing the binding of p53 with p300 and/or to inhibiting the E4 ubiquitin enzyme activity of p300. Further studies are needed to elucidate the precise mechanisms regarding the reciprocal regulation of p53 and p300 by Dox in cardiomyocytes.
